Table 4.
Circulating miRNAs as potential prognosis biomarkers of lung cancer.
| miRNA Signature | Sample Type | Type of Biomarker | Cohort Size | Method of Quantification and Normalization | References |
|---|---|---|---|---|---|
| miR-590-5p | Plasma | Prognosis (NSCLC) Low levels: lower median survival rates |
NSCLC (n = 80) and healthy controls (n = 80) |
qPCR; Cel-miR-39 |
Khandelwal et al., 2020 [101] |
|
Signature #1: miR-18a, miR-20a, miR-92a, miR-126, miR-210, and miR-19a; Signature 2: miR-18a, miR-20a, miR-92a, miR-210, and miR-126 |
Plasma | Prognosis (NSCLC) Signature #1: high levels, worse DFS Signature #2: high levels, sorter OS |
NSCLC (n = 196) |
qPCR; snRNA U6 |
Xu et al., 2018 [102] |
| miR-34a and miR-34c | Plasma | Prognosis (NSCLC) High levels miR-34a: prolonged DFS High levels miR-34c: longer OS |
NSCLC (n = 196) |
qPCR; snRNA U6 |
Zhao et al., 2017 [103] |
| miR-215-5p, miR-411-3p, miR-493-5p, miR-494-3p, miR-495-3p, miR-548j-5p, and miR-93-3p | Serum | Prognosis (NSCLC after nivolumab treatment) Signature associated with OS >6 months |
NSCLC (n = 51) |
Sequencing and qPCR; TMM normalization and endogenous miR-93-5p and miR-222-3p | Halvorsena et al., 2018 [104] |
NSCLC: non-small-cell lung cancer; DFS: disease-free survival; OS: overall survival; TMM: trimmed mean of M-values.